1.The cumulative survival rate of sandblasted, large-grit, acid-etched dental implants: a retrospective analysisThe cumulative survival rate of sandblasted, large-grit, acid-etched dental implants: a retrospective analysis
Haeji YUM ; Hee-seung HAN ; Kitae KIM ; Sungtae KIM ; Young-Dan CHO
Journal of Periodontal & Implant Science 2024;54(2):122-135
Purpose:
This retrospective study aimed to assess the long-term cumulative survival rate of titanium, sandblasted, large-grit, acid-etched implants over a 10-year follow-up period and investigate the factors affecting the survival rate and change in marginal bone loss (MBL).
Methods:
The study included 400 patients who underwent dental implant placement at the Department of Periodontology of Seoul National University Dental Hospital (SNUDH) between 2005 and 2015. Panoramic radiographic images and dental records of patients were collected and examined using Kaplan-Meier analysis, Cox proportional hazards regression analysis, and multiple regression analysis to determine the survival rates and identify any factors related to implant failure and MBL.
Results:
A total of 782 implants were placed with a follow-up period ranging from 0 to 16 years (mean: 8.21±3.75 years). Overall, 25 implants were lost, resulting in a cumulative survival rate of 96.8%. Comparisons of the research variables regarding cumulative survival rate mostly yielded insignificant results. The mean mesial and distal MBLs were 1.85±2.31 mm and 1.59±2.03 mm, respectively. Factors influencing these values included age, diabetes mellitus (DM), jaw location, implant diameter, bone augmentation surgery, and prosthetic unit.
Conclusions
This study found that the implant survival rates at SNUDH fell within the acceptable published criteria. The patients’ sex, age, DM status, implant location, implant design, implant size, surgical type, bone augmentation, and prosthetic unit had no discernible influence on long-term implant survival. Sandblasted, large-grit, acid-etched implants might offer advantages in terms of implant longevity and consistent clinical outcomes.
2.Clinical evaluation of 3.0-mm narrowdiameter implants: a retrospective study with up to 5 years of observation
InKyung HWANG ; Tae-Il KIM ; Young-Dan CHO
Journal of Periodontal & Implant Science 2024;54(1):44-52
Purpose:
This study aimed to evaluate the clinical outcomes of a single type of narrowdiameter implant (NDI) by investigating its survival rate and peri-implant marginal bone loss (MBL). In addition, variables possibly related to implant survival and MBL were investigated to identify potential risk factors.
Methods:
The study was conducted as a retrospective study involving 49 patients who had received 3.0-mm diameter TSIII implants (Osstem Implant Co.) at Seoul National University Dental Hospital. In total, 64 implants were included, and dental records and radiographic data were collected from 2017 to 2022. Kaplan-Meier survival curves and a Cox proportional hazard model were used to estimate the implant survival rate and to investigate the effects of age, sex, jaw, implant location, implant length, the stage of surgery, guided bone regeneration, type of implant placement, and the surgeon’s proficiency (resident or professor) on implant survival. The MBL of the NDIs was measured, and the factors influencing MBL were evaluated.
Results:
The mean observation period was 30.5 months (interquartile range, 26.75–45 months), and 6 out of 64 implants failed. The survival rate of the NDIs was 90.6%, and the multivariate Cox regression analysis showed that age was associated with implant failure (hazard ratio, 1.17; 95% confidence interval, 1.04–1.31, P=0.01). The mean MBL was 0.44±0.75 mm, and no factors showed statistically significant associations with greater MBL.
Conclusions
NDIs can be considered a primary alternative when standard-diameter implants are unsuitable. However, further studies are required to confirm their long-term stability.
3.The cumulative survival rate of dental implants with micro-threads:a long-term retrospective study
Dong-Hui NAM ; Pil-Jong KIM ; Ki-Tae KOO ; Yang-Jo SEOL ; Yong-Moo LEE ; Young KU ; In-Chul RHYU ; Sungtae KIM ; Young-Dan CHO
Journal of Periodontal & Implant Science 2024;54(1):53-62
Purpose:
This study aimed to evaluate the long-term cumulative survival rate (CSR) of dental implants with micro-threads in the neck over a 10-year follow-up period and to examine the factors influencing the survival rate of dental implants.
Methods:
This retrospective study was based on radiographic and dental records. In total, 151 patients received 490 Oneplant ® dental implants with an implant neck micro-thread design during 2006–2010 in the Department of Periodontology of Seoul National University Dental Hospital. Implant survival was evaluated using Kaplan–Meier analysis. Cox proportional hazard regression analysis was used to identify the factors influencing implant failure.
Results:
Ten out of 490 implants (2.04%) failed due to fixture fracture. The CSR of the implants was 97.9%, and no significant difference was observed in the CSR between externaland internal-implant types (98.2% and 97.6%, respectively,P=0.670). In Cox regression analysis, 2-stage surgery significantly increased the risk of implant failure (hazard ratio: 4.769, P=0.039). There were no significant differences in influencing factors, including sex, age, implant diameter, length, fixture type, location, surgical procedure, bone grafting, and restoration type.
Conclusions
Within the limitations of this retrospective study, the micro-thread design of the implant neck was found to be favorable for implant survival, with stable clinical outcomes.
4.Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy
Allison Y. ZHONG ; Sangwoo S. KIM ; Austin HOPPER ; Greg WHITE ; Sayuri MIYAUCHI ; Riley N. JONES ; Dan SCANDERBEG ; Loren K. MELL ; Elizabeth WEIHE ; Nathalie BOUTROS ; Stephen W. DOGGETT ; Andrew B. SHARABI
Radiation Oncology Journal 2024;42(3):237-243
Adenoid cystic carcinoma is a malignancy that is difficult to treat and often metastasizes to the lung. Systemic chemotherapies are not effective for this tumor type, thus local therapies are frequently used. Here, we report a case demonstrating the use of extensive ablative interventions in controlling the progression of metastatic adenoid cystic carcinoma. A patient with adenoid cystic carcinoma developed numerous metastases to his lungs and liver. Local ablative therapies including interstitial brachytherapy and SBRT were used to treat approximately 80 different metastases over the course of a decade. Over 850 brachytherapy seeds were implanted in this patient, and the tumor control and patient outcome were good. As of the most recent follow-up in March 2024, the patient has survived for approximately 12 years since his diagnosis of adenoid cystic carcinoma. To our knowledge, this case represents the most brachytherapy treatments reported in a single patient. It highlights the utility of interstitial brachytherapy and SBRT in treating extensive lung and liver metastases.
5.Nicotinamide as a therapeutic agent for bone diseases
Heein YOON ; Woo-Jin KIM ; Young-Dan CHO ; Hyun-Mo RYOO
International Journal of Oral Biology 2024;49(3):53-60
Nicotinamide (NAM), a water-soluble derivative of vitamin B3, has emerged as a potential therapeutic agent for bonerelated disorders. In particular, it promotes bone metabolism and alleviates delayed tooth eruptions associated with cleidocranial dysplasia (CCD). NAM serves as a precursor for nicotinamide adenine dinucleotide, a key coenzyme involved in cellular metabolism that plays an essential role in oxidative phosphorylation and mitochondrial function.Recent research has highlighted the capacity of NAM to enhance osteogenic differentiation and regulate the interaction between osteoblasts and osteoclasts, which is critical for maintaining bone homeostasis. Moreover, the effect of NAM in preventing delayed tooth eruptions in CCD models underscores its potential as a noninvasive therapeutic option. Considering its safety profile and therapeutic potential, NAM is a promising candidate for longterm treatment of bone diseases and prevention of age-related bone disorders.
6.Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy
Allison Y. ZHONG ; Sangwoo S. KIM ; Austin HOPPER ; Greg WHITE ; Sayuri MIYAUCHI ; Riley N. JONES ; Dan SCANDERBEG ; Loren K. MELL ; Elizabeth WEIHE ; Nathalie BOUTROS ; Stephen W. DOGGETT ; Andrew B. SHARABI
Radiation Oncology Journal 2024;42(3):237-243
Adenoid cystic carcinoma is a malignancy that is difficult to treat and often metastasizes to the lung. Systemic chemotherapies are not effective for this tumor type, thus local therapies are frequently used. Here, we report a case demonstrating the use of extensive ablative interventions in controlling the progression of metastatic adenoid cystic carcinoma. A patient with adenoid cystic carcinoma developed numerous metastases to his lungs and liver. Local ablative therapies including interstitial brachytherapy and SBRT were used to treat approximately 80 different metastases over the course of a decade. Over 850 brachytherapy seeds were implanted in this patient, and the tumor control and patient outcome were good. As of the most recent follow-up in March 2024, the patient has survived for approximately 12 years since his diagnosis of adenoid cystic carcinoma. To our knowledge, this case represents the most brachytherapy treatments reported in a single patient. It highlights the utility of interstitial brachytherapy and SBRT in treating extensive lung and liver metastases.
7.Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy
Allison Y. ZHONG ; Sangwoo S. KIM ; Austin HOPPER ; Greg WHITE ; Sayuri MIYAUCHI ; Riley N. JONES ; Dan SCANDERBEG ; Loren K. MELL ; Elizabeth WEIHE ; Nathalie BOUTROS ; Stephen W. DOGGETT ; Andrew B. SHARABI
Radiation Oncology Journal 2024;42(3):237-243
Adenoid cystic carcinoma is a malignancy that is difficult to treat and often metastasizes to the lung. Systemic chemotherapies are not effective for this tumor type, thus local therapies are frequently used. Here, we report a case demonstrating the use of extensive ablative interventions in controlling the progression of metastatic adenoid cystic carcinoma. A patient with adenoid cystic carcinoma developed numerous metastases to his lungs and liver. Local ablative therapies including interstitial brachytherapy and SBRT were used to treat approximately 80 different metastases over the course of a decade. Over 850 brachytherapy seeds were implanted in this patient, and the tumor control and patient outcome were good. As of the most recent follow-up in March 2024, the patient has survived for approximately 12 years since his diagnosis of adenoid cystic carcinoma. To our knowledge, this case represents the most brachytherapy treatments reported in a single patient. It highlights the utility of interstitial brachytherapy and SBRT in treating extensive lung and liver metastases.
8.Replantation of a Dental Implant at Sites of Previous Implant Failures using Guided Bone Regeneration
Hee-seung HAN ; Sungtae KIM ; Young-Dan CHO
Journal of implantology and applied sciences 2024;28(3):162-167
Here, we describe the successful replantation of a dental implant in a 69-year-old male patient who experienced early implant failure in the right mandibular posterior region (#46) owing to inadequate osseointegration. The patient presented with a narrow alveolar ridge and a class II dehiscence-type defect. A guided bone-regeneration (GBR) procedure using deproteinized bovine bone mineral and an absorbable collagen membrane was performed along with implant placement. Postoperative recovery was uneventful. After 6 weeks of postoperative recovery, healthy soft tissue healing was evident with no signs of infection or bone loss, demonstrating the effectiveness of GBR in managing implant failures with considerable bone defects.
9.Utilizing a high power light-emitting diode to induce apoptosis of uterine carcinosarcoma (malignant mixed mullerian tumor) cells through a bi-phasic effect
Gil Jae JUNG ; Su Jin LEE ; Yun Dan KANG ; Seung Hoon WOO ; Jong Soo KIM
Medical Lasers 2024;13(3):142-149
Background:
Malignant mixed mullerian tumor (MMMT), a carcinoma of the uterus, is a bi-phasic tumor composed of malignant epithelial and mesenchymal components. The treatment of MMMT remains a challenge despite advances in technology. This study is a preliminary investigation of the potential use of high power lightemitting diode (HPLED) modules as an alternative to laser therapy for cancer treatment.
Methods:
This study used 656 and 850 nm HPLEDs at 50 mW power output within a non-thermal range duration. The viability and proliferation of the cells were analyzed after irradiation with the HPLEDs.
Results:
A significant reduction in cancer cell viability was observed after irradiation with either the 656 or 850 nm HPLED.
Conclusion
This study shows the potential use of HPLEDs for cancer treatment.
10.Nicotinamide as a therapeutic agent for bone diseases
Heein YOON ; Woo-Jin KIM ; Young-Dan CHO ; Hyun-Mo RYOO
International Journal of Oral Biology 2024;49(3):53-60
Nicotinamide (NAM), a water-soluble derivative of vitamin B3, has emerged as a potential therapeutic agent for bonerelated disorders. In particular, it promotes bone metabolism and alleviates delayed tooth eruptions associated with cleidocranial dysplasia (CCD). NAM serves as a precursor for nicotinamide adenine dinucleotide, a key coenzyme involved in cellular metabolism that plays an essential role in oxidative phosphorylation and mitochondrial function.Recent research has highlighted the capacity of NAM to enhance osteogenic differentiation and regulate the interaction between osteoblasts and osteoclasts, which is critical for maintaining bone homeostasis. Moreover, the effect of NAM in preventing delayed tooth eruptions in CCD models underscores its potential as a noninvasive therapeutic option. Considering its safety profile and therapeutic potential, NAM is a promising candidate for longterm treatment of bone diseases and prevention of age-related bone disorders.

Result Analysis
Print
Save
E-mail